TY - JOUR
T1 - Synthesis, characterization of novel Sesamol substituted with thiazolidin-4-one derivatives and their evaluation for anti-oxidant and anti-cancer activities
AU - Yaswanatha Kumar, N. L.
AU - Bharathi, Kumar K.N.
AU - Mudgal, Jayesh
AU - VasanthaRaju, S. G.
AU - Manohara Reddy, S. A.
N1 - Funding Information:
One of the authors S.A. Manohara Reddy is grateful to the Science and engineering Research Board (SERB), New Delhi, India for providing financial support to carry out this project (Research grant no. SB/YS/LS-147/2014) and extended cooperation in the accomplishment of this work.
Publisher Copyright:
© 2020
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - In recent years for the development of novel anticancer hybrids with two or more pharmacophores of bioactive scaffolds to produce a single molecule by blending or linking has emerged as a simple strategy by providing an effective control on malignant process with improved biological potential. In this view, Sesamol being an active scaffold with important biological activities was modified and linked with various substitutions to afford thiazolidin-4-one derivatives. Herein, we report the synthesis, characterization of around twenty one compounds and their evaluation for antioxidant and anticancer potentials. The structures of these compounds were established by IR, 1H NMR, 13C NMR, and Mass. The compounds 1–15 were evaluated for in vitro cytotoxicity against three human lung cancer cell lines (A549, MCF-7 and HeLa), respectively. In preliminary MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity studies compounds 9 and 12 were found most effective. In A549 cancer cells the CTC50 (50% of cytotoxicity inhibition) were observed at 84.27 ± 2.7 & 91.98 ± 4.2 µg/ml, respectively. Moreover, in MCF-7 and HeLa cells the CTC50 values were observed at 174.3 ± 4 4.1, 69.15 ± 3.4 and 42.90 ± 3.5, 180.77 ± 4.6 µg/ml, respectively. Compounds 9 and 12 also exhibited best DNA damage activity via cell apoptosis when screened against Human breast cancer cell lines A549 and MCF-7 when compared to standard doxorubicin. In this study, Compounds 1, 9, 11 and 12 (at concentration 100 mg/kg/body wt.) were selected for in vivo anticancer activity against Dalton's Lymphoma Ascites bearing mice. Among the tested compounds all has shown modest antitumor activity and merited anti-cancer activity due to its cytotoxic properties when compared with standard methotrexate.
AB - In recent years for the development of novel anticancer hybrids with two or more pharmacophores of bioactive scaffolds to produce a single molecule by blending or linking has emerged as a simple strategy by providing an effective control on malignant process with improved biological potential. In this view, Sesamol being an active scaffold with important biological activities was modified and linked with various substitutions to afford thiazolidin-4-one derivatives. Herein, we report the synthesis, characterization of around twenty one compounds and their evaluation for antioxidant and anticancer potentials. The structures of these compounds were established by IR, 1H NMR, 13C NMR, and Mass. The compounds 1–15 were evaluated for in vitro cytotoxicity against three human lung cancer cell lines (A549, MCF-7 and HeLa), respectively. In preliminary MTT [3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] cytotoxicity studies compounds 9 and 12 were found most effective. In A549 cancer cells the CTC50 (50% of cytotoxicity inhibition) were observed at 84.27 ± 2.7 & 91.98 ± 4.2 µg/ml, respectively. Moreover, in MCF-7 and HeLa cells the CTC50 values were observed at 174.3 ± 4 4.1, 69.15 ± 3.4 and 42.90 ± 3.5, 180.77 ± 4.6 µg/ml, respectively. Compounds 9 and 12 also exhibited best DNA damage activity via cell apoptosis when screened against Human breast cancer cell lines A549 and MCF-7 when compared to standard doxorubicin. In this study, Compounds 1, 9, 11 and 12 (at concentration 100 mg/kg/body wt.) were selected for in vivo anticancer activity against Dalton's Lymphoma Ascites bearing mice. Among the tested compounds all has shown modest antitumor activity and merited anti-cancer activity due to its cytotoxic properties when compared with standard methotrexate.
UR - http://www.scopus.com/inward/record.url?scp=85099576841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099576841&partnerID=8YFLogxK
U2 - 10.1016/j.rechem.2020.100095
DO - 10.1016/j.rechem.2020.100095
M3 - Article
AN - SCOPUS:85099576841
SN - 2211-7156
VL - 3
JO - Results in Chemistry
JF - Results in Chemistry
M1 - 100095
ER -